Effect of SCT on 5-year outcome of patients in the SR and HR groups with molecular failure after consolidation (week 16)
| Parameter . | N . | No SCT . | SCT . | |||
|---|---|---|---|---|---|---|
| n . | % ± SD . | n . | % ± SD . | P . | ||
| Continuous complete remission | 120 | 63 | 12 ± 5 | 57 | 66 ± 8 | < .0001 |
| Continuous complete remission (landmark analysis) | 60 | 35 | 17 ± 7 | 25 | 73 ± 10 | .0001 |
| Disease-free survival | 120 | 63 | 11 ± 4 | 57 | 44 ± 8 | < .0001 |
| Disease-free survival (landmark analysis) | 60 | 35 | 16 ± 7 | 25 | 50 ± 10 | .004 |
| Overall survival | 120 | 63 | 33 ± 7 | 57 | 54 ± 8 | .06 |
| Parameter . | N . | No SCT . | SCT . | |||
|---|---|---|---|---|---|---|
| n . | % ± SD . | n . | % ± SD . | P . | ||
| Continuous complete remission | 120 | 63 | 12 ± 5 | 57 | 66 ± 8 | < .0001 |
| Continuous complete remission (landmark analysis) | 60 | 35 | 17 ± 7 | 25 | 73 ± 10 | .0001 |
| Disease-free survival | 120 | 63 | 11 ± 4 | 57 | 44 ± 8 | < .0001 |
| Disease-free survival (landmark analysis) | 60 | 35 | 16 ± 7 | 25 | 50 ± 10 | .004 |
| Overall survival | 120 | 63 | 33 ± 7 | 57 | 54 ± 8 | .06 |